On 29 October 2014, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as “Fosun Pharma” or the “Company”, Stock Code: 600196-SH, 02196-HK) announced its third quarterly results as at 30 September 2014. During the reporting period, Fosun Pharma achieved an operating revenue of RMB8,661 million, representing a year-on-year increase of 22.50%. The net profit attributable to shareholders of the Company amounted to RMB1,575 million, representing a year-on-year increase of 65.64% as compared with RMB951 million for the first three quarters of 2013.

The report shows that in the third quarter of 2014, the overall operating revenue of Fosun Pharma amounted to RMB 3,123 million, representing a year-on-year increase of 21.92% as compared with RMB 2,561 million for the third quarter of 2013. The net profit attributable to shareholders of the Company amounted to RMB557 million for the third quarter, increased by 64.97% as compared with RMB338 million for the same period in 2013.

Fosun Pharma completed the privatization of Chindex in the third quarter. In the meantime, a series of merger and cooperation projects were actively carried forward in the healthcare sector. In August of this year, Fosun Pharma, through Shanghai Yicheng Hospital Investment Management Company Limited, a wholly-owned subsidiary of Fosun Pharma, and Taizhou Municipal Investment Company Limited, a company wholly owned by Taizhou Municipal Hospital jointly established the Taizhou Zanyang Medical Care Investment Management Company Limited with an investment of over RMB 680 million, which is deemed as an alternative innovation of the Company in the healthcare sector.

In addition, the pharmaceutical manufacturing sector of the Company kept good sales results. The Company continuously paid attention to innovation and R&D and increased efforts into R&D. The management of the Company expressed that the Company would continue to push forward the strategy of “organic growth, external expansion and integrated development”, adhere to its business philosophy of “Innovation for Good Health”, focus on its core pharmaceutical businesses and persist in product innovation and management improvement. In the meantime, it will seize the opportunity of the current pharmaceutical market and industry and vigorously develop the healthcare industry.

About Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”) was established in 1994. As a leading company in China’s pharmaceutical and healthcare industry, Fosun Pharma was listed on the Shanghai Stock Exchange and on the main board of the Hong Kong Stock Exchange(stock code: 600196-SH, 02196-HK) in August 1998 and October 2012.

Fosun Pharma strategically operates in several key sectors on the value-chain of the pharmaceutical and healthcare industry. Our main business includes pharmaceutical research and development, manufacturing, distribution and retailing, medical devices and diagnostic products as well as healthcare services. The company owns a national-level Technology Center and has a R&D team with international perspective. We had been continuously focusing on innovative research and development in therapeutic areas such as metabolism and alimentary tract, cardiovascular system, central nervous system, anti-tumor as well as anti-infective treatment.

Our commitment is “Innovation for Good Health”. In future, Fosun Pharma will continue to implement its strategy of organic growth with external expansion and integrated business operation. We are dedicated to become a first class enterprise in major global healthcare market. For more information on Fosun Pharma, please visit www.fosunpharma.com